Biogen Inc BIIB:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
271.21 -5.36   -1.94%1,803,3911.7M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 4/28/2017

Latest News Headlines for Biogen Inc

Biogen Reports First Quarter 2017 Revenues of -4-

(D) Cambridge manufacturing facility rationalization costs reflect additional depreciation, the write-down of excess inventory and other direct costs associated with our decision to vacate and cease manufacturing in Cambridge, MA and vacate our warehouse in Somerville, MA. Additional depreciation expense, which totaled $14.0 million for the three months ended December 31, 2016, is included in cost of sales, excluding amortization of acquired intangible assets in our condensed consolidated statements of income. Also reflected in this amount for the three months ended December 31, 2016 are charges of $1.4 million for the write-down of excess inventory, which are included in cost of sales, excluding amortization of acquired intangible assets in our condensed consolidated statements of income.

Biogen Reports First Quarter 2017 Revenues of -3-

------------ -------- Total cost and expenses 1,786.4 1,348.4 ------------ --------

Biogen Reports First Quarter 2017 Revenues of -2-

earlier access to patients for medicines that fulfill unmet medical needs. SPINRAZA is the first treatment for spinal muscular atrophy to be recommended by the CHMP for approval in the EU.

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

BIIB
Biogen Inc
3.83%
Shire PLC (ADR)
3.86%
Allergan plc
16.12%
Novo Nordisk A/S (ADR)
7.86%
-2.10%
Mylan NV
BIIB
Biogen Inc
0.00%
Shire PLC (ADR)
0.51%
Allergan plc
1.15%
Novo Nordisk A/S (ADR)
3.47%
Mylan NV
0.00%
-1.94%
BIIB
Biogen Inc
-0.49%
Shire PLC (ADR)
Allergan plc
0.33%
-0.26%
Novo Nordisk A/S (ADR)
-0.98%
Mylan NV
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; BIIB061; BIIB054; BIIB067, and BIIB068.

https://www.biogen.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open277.09
Previous Close276.57
Day High277.28
Day Low271.06
52 Week High8/2/2016 | 307.325
52 Week Low6/27/2016 | 205.4247
% Off 52 Week High(11.75)%
% Off 52 Week Low32.02%
Beta (5 Yr)0.80
Volatility Avg4/28/2017 | 30.81
10-Day Avg. Volume1,657,294
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)3/31/2017 | 15.95
P/E Ratio3/31/2017 | 17.0
Market CapLarge Cap | 57.5B
Shares Outstanding212.12M
Float211.5M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.60M
Short Ratio2.0
Short % of Float1.21%
As of 4/15/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.